It is still challenging to treatment with metastatic prostate cancer(mPCa).In recent years,with the development of radionuclide drugs,the novel radiopharmaceuticals have been proved to improve the prognosis of patients with metastatic castration-resistant prostate cancer such as radium-223 and 177 Lu-prostate-specific membrane antigen-617(177 Lu-PSMA-617).Some radiopharmaceuticals have also been explored for the treatment of metastatic hormone-sensitive prostate cancer.This article reviewed the research progress of various radionuclides in treatment of mPCa based on various clinical trials.
维普
万方数据
